TB-500

Overview

What is TB-500?

TB-500 is a synthetic fragment reproducing part of the naturally occurring protein Thymosin Beta-4. It is studied for systemic tissue repair, cell migration, wound healing and flexibility, and is widely used in regenerative and athletic recovery research contexts.

• Tissue Repair
• Wound Healing
• Flexibility
• Systemic Recovery

What the research reports

Reported benefits of TB-500

Outcomes described across the published TB-500 literature and ongoing study. Read each as research context rather than a promised personal result.

1. 01

   Systemic tissue repair work

   Thymosin Beta-4 sequesters actin and supports cell migration, which underpins its study in wound repair across several tissue types. Reported in research settings.

2. 02

   Wound healing study record

   A 2016 review described faster dermal repair in patients with pressure ulcers and chronic wounds treated with thymosin beta-4. Reported in research settings.

3. 03

   Flexibility and mobility study

   Often researched for connective tissue pliability after injury. No published human trial has directly measured flexibility as a primary outcome in this indication.

4. 04

   Inflammation modulation study

   Often researched for connective tissue pliability after injury. No published human trial has directly measured flexibility as a primary outcome in this context.

5. 05

   Cardiac and regenerative study

   Preclinical research explores cardiac cell survival and regeneration through reactivation of embryonic repair programmes in adult tissue. Reported in research settings.

Clinical evidence

TB-500 clinical evidence summary

The published TB-500 record, labeled by strength so you can see what is settled and what is still emerging.

Interactions

How TB-500 pairs with other peptides

BPC-157 peptide

Synergistic for tissue repair. BPC-157 drives angiogenesis while TB-500 modulates actin and cell migration.

GHK-Cu peptide

Often combined in repair blends. Both support remodelling, with GHK-Cu adding collagen and elastin signalling.

KPV peptide

No known negative interaction. KPV targets inflammatory signalling while TB-500 targets actin and cell movement.

Ipamorelin

No known negative interaction. Growth hormone secretagogues act on a separate axis to actin regulation.